

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7670205

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM	11/30/2022
RECEIVING PARTY DATA	
Name:	VIKAS KUNDRA
Street Address:	7100 CRAIL DRIVE
City:	BETHESDA
State/Country:	MARYLAND
Postal Code:	20817
PROPERTY NUMBERS Total: 4	
Property Type	Number
Application Number:	16659986
Application Number:	15647840
Application Number:	13821541
Application Number:	61380920
CORRESPONDENCE DATA	
Fax Number:	(512)334-2999
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	5123342900
Email:	jnorman@phiplaw.com
Correspondent Name:	PARKER HIGHLANDER PLLC
Address Line 1:	1120 S. CAPITAL OF TEXAS HWY.
Address Line 2:	BUILDING ONE, SUITE 200
Address Line 4:	AUSTIN, TEXAS 78746
ATTORNEY DOCKET NUMBER:	KUND.P0002US.D2
NAME OF SUBMITTER:	JENNIFER NORMAN-WOLFE
SIGNATURE:	/Jennifer Norman-Wolfe/
DATE SIGNED:	11/30/2022
Total Attachments: 1	
source=KUND.P0002US.D2 - Executed Assignment - Executed by UT (01091472xCCC41)#page1.tif	

ASSIGNMENT DOCUMENT

WHEREAS, The Board of Regents of The University of Texas System, having a place of business at 201 West Seventh Street, Austin, Texas 78701 (hereinafter referred to as "BOARD"), owns all right, title, and interest in and to the following applications:

- U.S. Patent Application No. 16/659,986 filed on October 22, 2019 entitled "Tumor Treatment Methods Using Cells That Localize To The Tumor";
- U.S. Patent Application No. 15/647,840 filed on July 12, 2017 entitled "Somatostatin Receptor-Based Cancer Therapy";
- U.S. Patent Application No. 13/821,541 filed on September 8, 2011 entitled "Somatostatin Receptor-Based Cancer Therapy";
- International Patent Application No. PCT/US2011/050803 filed on September 8, 2011 entitled "Somatostatin Receptor-Based Cancer Therapy";
- Brazil Patent Application No. 11 2013 005711 4 filed on September 8, 2011 entitled "Somatostatin Receptor-Based Cancer Therapy";
- Canada Patent Application No. 2,810,838 filed on September 8, 2011 entitled "Somatostatin Receptor-Based Cancer Therapy";
- Europe Patent Application No. 11824117.3 filed on September 8, 2011 entitled "Somatostatin Receptor-Based Cancer Therapy";
- India Patent Application No. 2330/DELNP/2013 filed on September 8, 2011 entitled "Somatostatin Receptor-Based Cancer Therapy"; and
- U.S. Provisional Patent Application No. 61/380,920 filed on September 8, 2010 entitled "Somatostatin Receptor-Based Cancer Therapy".


WHEREAS, I represent that I, Vikas Kundra, am a creator of the technology represented by the Patents ("Creator"). Creator desires to own BOARD'S entire right, title, and interest in and to the Patents;

WHEREAS, upon full execution of this Assignment Document by the Creator, the Creator will own the whole of BOARD'S entire right, title, and interest in and to the Patents.

NOW THEREFORE, be it known that, for good and valuable consideration, the receipt of which is hereby acknowledged, BOARD hereby sells, assigns, and transfers to Creator, and his/her, lawful successors and assigns, BOARD's entire right, title, and interest in and to the Patents, together with all reissues, reexaminations and extensions of the Patents.

IN TESTIMONY WHEREOF, each party has caused its authorized representative to execute this Assignment Document.

**THE BOARD OF REGENTS OF
THE UNIVERSITY OF TEXAS SYSTEM**

By 
Marc Vockell, Associate General Counsel
The University of Texas System
Date November 30, 2022

CREATOR

By _____
Vikas Kundra

Date _____